CD7 Inhibitors

Staurosporine is a potent kinase inhibitor that can inhibit a wide range of protein kinases. Given that CD7 is a protein that can be phosphorylated, staurosporine could inhibit kinases that phosphorylate CD7, leading to its functional inhibition.

Chelerythrine is known to inhibit protein kinase C (PKC). Since PKC can phosphorylate a plethora of proteins, including those in T-cell signaling where CD7 is involved, the inhibition of PKC can lead to a reduction in CD7 functional activity.

Sphingosine serves as an inhibitor of protein kinase C (PKC). As PKC is involved in signaling pathways of T-cells, the inhibition of PKC by sphingosine can result in decreased CD7 signaling.

Bisindolylmaleimide I selectively inhibits protein kinase C (PKC). By inhibiting PKC, which is involved in T-cell activation where CD7 is present, it can lead to the functional inhibition of CD7.

Ro-31-8220 is a potent protein kinase C inhibitor. Inhibiting PKC can disrupt the phosphorylation status of proteins within the T-cell receptor signaling pathway, potentially inhibiting the activity of CD7.

Gö 6983 is a broad-spectrum protein kinase C inhibitor. By blocking PKC, which plays a role in T-cell activation, this could result in functional inhibition of CD7.

Gö 6976 is a protein kinase C inhibitor that is more selective towards certain PKC isoforms. Inhibition of these PKC isoforms can lead to a decrease in CD7 function as part of T-cell signaling.

Rottlerin is a reported inhibitor of several kinases, including some PKC isoforms. By inhibiting these kinases, rottlerin can diminish phosphorylation-dependent signaling involving CD7.

Calphostin C is a potent inhibitor of protein kinase C. This inhibition can lead to a decrease in the phosphorylation of proteins involved in T-cell receptor signaling and subsequent inhibition of CD7 activity.

Sotrastaurin is an inhibitor of protein kinase C. By inhibiting PKC, sotrastaurin can disrupt the downstream signaling that involves CD7, inhibiting its function.